The US Food and Drug Administration (FDA) has granted 510(k) clearance for the Johnson & Johnson (J&J) Medical Devices Companies unit DePuy Synthes’ VELYS Robotic-Assisted Solution for use with the ATTUNE Total Knee System.
The solution is designed from technology developed by Orthotaxy, a company J&J Medical Devices Companies acquired in 2018.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The table-mounted solution can be integrated into any operating room (OR). It adapts to the surgeon’s workflow and can offer them the control they are accustomed to and carry out precise bony cuts.
Using innovative planning capabilities, proprietary technology, and advanced design, the VELYS Robotic-Assisted Solution can help surgeons to resect bones that align and position the implant relative to the soft tissue during total knee replacement without requiring pre-operative imaging.
Furthermore, it streamlines knee replacement surgery by offering valuable insights, versatile execution, and verified performance.
The company noted that the solution works with the ATTUNE Total Knee, which can enhance patient-reported outcomes by working in coordination with the anatomy of the patient to offer stability and motion, using proprietary technologies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe solution will be included in VELYS Digital Surgery Platform of connected technologies.
DePuy Synthes Franchise company group chairman Aldo Denti said: “Coupled with the ATTUNE Total Knee, the VELYS Robotic-Assisted Solution is highly differentiated and can help improve clinical outcomes and increase patient satisfaction, providing a more attractive clinical solution to current options on the market.
“With the addition of the VELYS Robotic-Assisted Solution to our VELYS Digital Surgery Platform, we are continuing our vision to be the most personalised and connected orthopaedics company.”
In September 2019, DePuy Synthes Products announced the acquisition of the assets of JointPoint to enhance surgical accuracy and reproducibility in hip replacement.
